Feature|Videos|September 30, 2024
The Regulatory Stance on Oligonucleotide Enantiomers
Author(s)LCGC Editors
The panel dives into the regulatory stance on oligonucleotide enantiomers. The role of batch-to-batch reproducibility, new drug application (NDA) filing, and current guidelines are covered.
Advertisement
Episodes in this series
Regulatory guidelines must be considered when discussing oligonucleotide analysis and enantiomers. The panel reviews the current regulatory stance on this topic and common analytical bottlenecks relative to regulatory compliance.
Advertisement
Advertisement
Advertisement
Trending on LCGC International
1
UHPLC-MS/MS Tracks Drug Potency on the International Space Station
2
Vol 3 No 5 LCGC International July/August 2026 North American PDF
3
The Biggest Gap in NIAS Testing for Food Contact Materials
4
Chromatography Tracks Pesticides on Strawberries
5